ICON Public Limited (NASDAQ:ICLR) Receives $339.44 Average Price Target from Analysts

Shares of ICON Public Limited (NASDAQ:ICLRGet Free Report) have been assigned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have covered the stock in the last year is $339.44.

ICLR has been the topic of several research analyst reports. Mizuho reissued a “buy” rating and issued a $346.00 price objective on shares of ICON Public in a research report on Thursday, April 4th. TD Cowen raised their target price on ICON Public from $343.00 to $349.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Evercore ISI cut their price target on shares of ICON Public from $350.00 to $330.00 and set an “outperform” rating for the company in a report on Friday, April 26th. Barclays upped their price target on shares of ICON Public from $325.00 to $355.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Finally, Truist Financial lifted their price objective on ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a research note on Friday, February 23rd.

Check Out Our Latest Analysis on ICON Public

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Bruce G. Allen Investments LLC purchased a new stake in ICON Public in the 4th quarter worth approximately $25,000. Riverview Trust Co purchased a new stake in ICON Public in the first quarter worth $31,000. Livelsberger Financial Advisory bought a new stake in ICON Public in the fourth quarter valued at $29,000. Pinnacle Bancorp Inc. increased its position in ICON Public by 110.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 55 shares during the period. Finally, GAMMA Investing LLC bought a new position in ICON Public in the 4th quarter worth $37,000. Institutional investors own 95.61% of the company’s stock.

ICON Public Price Performance

Shares of NASDAQ:ICLR opened at $321.06 on Wednesday. ICON Public has a 1-year low of $204.38 and a 1-year high of $344.77. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.36. The stock has a market cap of $26.49 billion, a PE ratio of 39.06, a price-to-earnings-growth ratio of 1.49 and a beta of 1.18. The stock’s fifty day simple moving average is $314.62 and its two-hundred day simple moving average is $294.33.

ICON Public (NASDAQ:ICLRGet Free Report) last issued its quarterly earnings data on Wednesday, April 24th. The medical research company reported $3.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.30 by $0.08. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. The business had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.09 billion. As a group, analysts forecast that ICON Public will post 14.41 EPS for the current fiscal year.

ICON Public Company Profile

(Get Free Report

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Articles

Analyst Recommendations for ICON Public (NASDAQ:ICLR)

Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.